Annotation Detail
Information
- Associated Genes
- ERBB2
- Associated Variants
-
ERBB2 AMPLIFICATION
(
ENST00000269571.10 )
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) - Associated Disease
- Her2-receptor positive breast cancer
- Source Database
- CIViC Evidence
- Description
- CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer. Patients were HER2-positive by IHC3+ or FISH, and patients who had received prior hormonal treatment or adjuvant/neo-adjuvant therapy with or without trastuzumab for longer than 12 months before randomization were also eligible. The two arms of the study were trastuzumab and docetaxel with either placebo or pertuzumab. Median PFS in the placebo arm was 12.4 months while in the petuzumab arm 18.5 months was achieved. Median OS in the control arm was 40.8 months and 56.5 months with pertuzumab. These strong results make a case for dual antibody blockade in first line treatments of HER2-positive metastatic breast cancer.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1077
- Gene URL
- https://civic.genome.wustl.edu/links/genes/20
- Variant URL
- https://civic.genome.wustl.edu/links/variants/306
- Rating
- 5
- Evidence Type
- Predictive
- Disease
- Her2-receptor Positive Breast Cancer
- Evidence Direction
- Supports
- Drug
- Docetaxel,Trastuzumab,Pertuzumab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25693012
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Docetaxel | Sensitivity | true |
| Pertuzumab | Sensitivity | true |
| Trastuzumab | Sensitivity | true |